GlassScriptPhysician profile
Basit Qayyum
NPI 1790793537
$3,235.17
in general payments reported to CMS, 2019-2025
25 companies · $542 in 2025
The $542 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $404 · 2021: $440 · 2022: $353 · 2023: $502 · 2024: $448 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,491.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $473.06 | 2020-2025 | |
| Bioxcel Therapeutics, INC. | $346.16 | 2023-2024 | Igalmi |
| Horizon Therapeutics Plc | $308.25 | 2019-2020 | |
| Abbvie INC. | $292.53 | 2019-2024 | |
| Lilly USA, LLC | $221.61 | 2019-2024 | Amyvid, Kisunla |
| Ucb, INC. | $193.86 | 2025 | Bimzelx |
| Amgen INC. | $151.15 | 2022-2025 | Krystexxa, Evenity, Prolia |
| Biogen, INC. | $145.74 | 2021 | |
| Idorsia Pharmaceuticals US INC | $142.30 | 2022-2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $138.90 | 2019 | |
| Esperion Therapeutics, INC. | $124.97 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.54 | 2020 | |
| Kyowa Kirin, INC. | $110.80 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $72.87 | 2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $72.86 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $60.44 | 2019 | |
| Gilead Sciences, INC. | $55.84 | 2019-2025 | |
| Avanir Pharmaceuticals, INC. | $50.80 | 2019 | |
| Axsome Therapeutics, INC. | $37.93 | 2023-2024 | Auvelity |
| Amarin Pharma, INC. | $24.98 | 2023 | |
| Glaxosmithkline, LLC. | $24.94 | 2020 | |
| Rigel Pharmaceuticals, INC. | $19.93 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.92 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.06 | 2019 | |
| Seagen INC. | $12.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basit Qayyum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.